For over 40 years, Minaris Advanced Testing has established the benchmark for analytical and biosafety services for biologics, including advanced therapies, monoclonal antibodies, recombinant proteins, and vaccines.
Today, our 140,000 ft² state-of-the-art facility in Philadelphia is purposefully designed to enable contract testing services that help our clients reach patients safely, reliably, and in a timely manner.
In 2025, Altaris Capital unified the operations of Advanced Therapies, LLC and Minaris Regenerative Medicine under Minaris Advanced Therapies, with testing as a cornerstone of the business. This integration created a purpose-built CDMO where analytics and QC are embedded at every stage of the lifecycle. By combining manufacturing and testing under one global quality system, Minaris reduces the bottlenecks that often delay timelines.
Our dedicated 140,000 ft² Philadelphia laboratory is purpose-built for advanced testing. In 2021, the facility expanded throughput and increased capacity for QC microbiology, molecular and virology laboratories. Digital platforms, electronic records, and real-time dashboards ensure data integrity and regulator-ready results across modalities.
Minaris Advanced Testing supports over 25 commercial products and has developed more than 1,700 assays used in IND, IMPD, and BLA submissions. The FDA and EMA inspected our Philadelphia facility, and our methods are accepted by regulators worldwide. From biosafety and viral clearance to potency and stability, we deliver audit-ready data packages that anticipate agency expectations, minimize questions, and accelerate approvals.
Every step in our history reflects a core belief: patients cannot wait. We invested early in biosafety, broadened into biologics, and integrated testing with manufacturing to ensure seamless quality. Sponsors choose Minaris Advanced Testing for:
Efficiency:
Use of modern technologies and streamlined processes mean reduced turnaround times
Customer Centricity:
We maintain a customer-first focus, working with each account to understand the unique requirements of their program
Reliability:
Cross-modality expertise and validated methods provide reliable results
Scalability:
Infrastructure and systems support programs from early studies through commercial supply
As therapies become more complex, testing will remain central to success. Minaris Advanced Testing is investing in next-generation analytics, automation, and digital QC to ensure identity, purity, potency, and safety keep pace with innovation. Whether advancing a novel vaccine, scaling an allogeneic platform, or validating comparability for commercial supply, our mission remains constant: to deliver audit-ready results that accelerate the transition of therapies from the lab to the patient.
Testing Resources
Through our Knowledge Center, we share data-driven insights and best practices from across the industry to help you stay ahead of evolving expectations.
intro-section does not exist
Accurate, timely, and compliant testing is critical to advancing complex therapies. Minaris Advanced Testing delivers a comprehensive suite of GMP biosafety and characterization services designed to support every stage of your program, from early research through IND, clinical and commercial requirements. Our team provides the experience, responsiveness and support you need. Get in touch today.
